Our finding suggests a theoretical basis for the use of pioglitazone in treating AD, by demonstrating the efficacy of low-dose pioglitazone in the improvement of memory impairment and Aβ pathology-related LRP1 expression in a mouse model of AD. This evidence concerns the gene LRP1 and Alzheimer disease.